Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2b Placebo-Controlled Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy School-Age Children to Assess Immunological Response and Safety of a Single Dose BPZE1 With/Without Coadministration of Tdap (Boostrix™)

NCT05116241 is registered in ClinicalTrials.gov with ILiAD Biotechnologies as lead sponsor.

NCT NCT05116241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05116241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2b Placebo-Controlled Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy School-Age Children to Assess Immunological Response and Safety of a Single Dose BPZE1 With/Without Coadministration of Tdap (Boostrix™)
Lead sponsor
ILiAD Biotechnologies
Phase
Phase 2
Overall status
Completed
Start date
November 11, 2021
Completion date
May 15, 2024
Enrollment
368 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

bordetella pertussis, whooping cough